A carregar...
Clinical benefit from afatinib in an advanced squamous cell lung carcinoma patient harboring HER2 S310Y mutation: a case report
BACKGROUND: HER2 mutations are identified in approximately 2% of non-small-cell lung cancer (NSCLC) cases and are predominantly observed in non-smokers, females, and adenocarcinoma patients. Although afatinib is recommended for treating NSCLC patients with HER2 mutation, the therapy is most efficaci...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6287414/ https://ncbi.nlm.nih.gov/pubmed/30584328 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S182812 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|